Pharmaceutics

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

The groninger Group has acquired Reinraumtechnik Ulm GmbH (RTU). With this strategic move, the family-owned company headquartered in Crailsheim not only expands its technological portfolio but also strengthens its expertise in a field that is crucial to the pharmaceutical industry: cleanroom and isolator technology.

Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

Diabetics have a higher risk of colorectal cancer and often a poorer prognosis after developing the disease. The biological mechanisms behind this association were largely unknown. A research team at the German Cancer Research Center (DKFZ) has now discovered that tumors with a low number of immune cells appear to be particularly susceptible to the harmful effects of diabetes.

Study led by the University of Tübingen: many non-antibiotics weaken the natural protective function of the intestine – with consequences for the colonization with pathogenic bacteria

AI-supported image recognition accelerates identification of zebrafish mutants - 16/07/2025

EmbryoNet AI automatically identifies developmental disorders

In complex organisms, embryonic development is tightly regulated by intricate signalling pathways. When these pathways are disrupted, they can lead to characteristic developmental defects that are not easy to detect with the naked eye. Developmental biologist Prof. Dr. Patrick Müller from the University of Konstanz has developed EmbryoNet, an AI-powered software tool that uses image analysis to reliably identify such developmental disorders.

Scientists have been working on the artificial production of blood for several decades. Making a new discovery, researchers from the Institute for Cellular Biology and Immunology Thurgau at the University of Konstanz, in collaboration with Queen Mary University of London, have come an important step closer to this goal.

Computer tool opens up new ways to address antibiotic resistance - 02/07/2025

PhARIS identifies effective phages against multi-resistant bacteria

Bacteriophages - viruses that specifically attack and destroy bacteria - are emerging as promising alternatives to antibiotics in the fight against drug-resistant infections. To speed this effort, researchers have created PhARIS, a computational tool that mines genomic data to pinpoint phages that are effective against S. aureus. By rapidly matching phage and pathogen, PhARIS can accelerate the development of targeted phage therapies.

Acquisition will strengthen the mRNA-based cancer immunotherapy candidates, marking BioNTech’s milestone in its oncology strategy. Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. All-stock acquisition has potential to create value for both companies’ shareholders given their complementary capabilities, focus on mRNA, and shared vision.

On May 9, 2025, representatives from the life sciences industry in North Carolina and Baden-Württemberg met in Stuttgart for professional exchange. The goal of the event was to explore opportunities for collaboration in biotechnology, medical technology, and pharmaceutical research.

Baden-Württemberg AI Alliance - 08/04/2025

Achieving widespread use of AI

Artificial intelligence presents both opportunities and risks. The Baden-Württemberg AI Alliance is dedicated to fostering collaboration among AI stakeholders to ensure that AI solutions deliver tangible benefits to citizens and businesses across the state. The alliance will also place greater emphasis on advancing AI applications within the healthcare sector.